The Biased GLP-1 Signal: Ecnoglutide’s 35% Edge Over Semaglutide Is the Opening Shot in Obesity’s Next Competitive War
Sciwind's ecnoglutide beat semaglutide by 35% on weight loss in a head-to-head trial—and it signals a coming wave of...
Semaglutide
Semaglutide’s Patent Cliff Isn’t a Generics Story — It’s a Market Architecture Story
As semaglutide patents begin expiring across key markets, the real disruption isn't Novo Nordisk losing revenue — it's that...